Overview

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a groundbreaking immunotherapy approach in cancer treatment. It involves modifying a patient's T cells to express a receptor that targets specific cancer cells. These engineered T cells are then infused into the patient's body to enhance the immune system's ability to recognise and destroy cancer cells, offering promising results in certain blood cancers.

The importance of CAR-T therapy in children lies in its transformative impact on the treatment of certain paediatric cancers. Traditional therapies, while effective for many, may fall short in cases of relapsed or refractory hematologic malignancies in children. Car-T therapy emerges as a crucial lifeline, offering a personalised and targeted approach to combating these challenging conditions. By harnessing the body's immune system and genetically modifying T cells, CAR-T therapy enhances cancer cell recognition and eradication precision. This precision is vital in paediatric cases where standard treatments may have limited success or carry substantial side effects.

Understanding CAR-T Therapy

CAR-T therapy is an immunotherapy that harnesses the power of the patient's immune system to target and eliminate cancer cells. The process involves extracting T cells (white blood cells) from the patient's body, genetically modifying them to express chimeric antigen receptors specific to cancer cells, and then infusing the modified T cells back into the patient.

[caption id="attachment_23177" align="alignnone" width="1754"] Chimeric antigen receptor T cell[/caption]

How CAR-T Therapy Works?

It involves many steps; let’s check in detail.

T-cell collection: T cells are extracted from the patient's blood through leukapheresis.

The collected T cells are then transported to a specialised laboratory.

- Genetic changes: In the laboratory, the T cells undergo genetic modification to express chimeric antigen receptors (CARs). CARs are synthetic receptors designed to recognise specific antigens on the surface of cancer cells.
- Cell expansion: The modified T cells are cultured and allowed to multiply, creating a large population of CAR-T cells.
- Infusion: The expanded CAR-T cells are infused back into the patient, where they seek out, and destroy cancer cells.

[caption id="attachment_23178" align="alignnone" width="1000"] Working of CAR-T therapy[/caption]

Application in Paediatric Oncology

CAR-T therapy has shown promising results in paediatric patients with certain types of leukaemia and lymphoma, particularly those who have not responded to standard treatments or have experienced relapse. Some of the critical paediatric cancers targeted by CAR-T therapy include

- Acute Lymphoblastic Leukaemia (ALL). CAR-T therapy has demonstrated significant success in treating children with relapsed or refractory ALL.
- Non-Hodgkin Lymphoma (NHL): Certain types of NHL in children, such as diffuse large B-cell lymphoma (DLBCL), have shown positive responses to CAR-T therapy.
- Neuroblastoma: Early clinical trials are exploring the potential of CAR-T therapy in paediatric neuroblastoma, a challenging form of cancer.

Challenges and Considerations

While CAR-T therapy holds immense promise, there are challenges and considerations specific to its application in paediatric oncology:

- Unique Toxicities: Children may experience unique toxicities associated with CAR-T therapy, such as cytokine release syndrome (CRS) and neurotoxicity.
- Long-term Effects: The long-term effects of CAR-T therapy on paediatric patients, including its impact on growth and development, are still being studied.
- Access and Affordability: Ensuring widespread access to CAR-T therapy for children, including addressing cost barriers, is critical.

When to Consult a Doctor

You can also get in touch with the expert doctors at Narayana Healthcare based in your city to get immediate attention and medical support during injuries, health disorders or any other health concern.

Conclusion

CAR-T therapy represents an effective step in the treatment of paediatric cancers, offering new hope for children facing limited treatment options. As research and clinical trials continue, paediatric oncology is poised to witness further advancements, ultimately improving young cancer patients' prognosis and quality of life. The collaboration between researchers, healthcare providers, and families is crucial in realising the full potential of CAR-T therapy in the fight against childhood cancer.

References

- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/
- https://www.sciencedirect.com/science/article/pii/S0753332221012993